Member Profile

Dr. Alfonso Iorio

Alfonso Iorio is Professor and Chair, Department of Health Research Methods, Evidence, and Impact at McMaster University Canada. He is Director of the Health Information Research Unit (HiRU, http://hiru.mcmaster.ca/hiru) and of the Hamilton-Niagara Hemophilia Program.

He received his medical and PhD degrees from the University of Perugia, Italy.

He is the Principal Investigator of the Web Application for Population Pharmacokinetic in Hemophilia (WAPPS) project (www.wapps-hemo.org), co-investigator of the Patient Reported Outcomes, Burden, and Experiences (PROBE), and Chair of the Canadian Bleeding Disorders Registry (CBDR).

He is past-chair of the WFH Data and Demographics committee, and co-chair of the World Bleeding Disorders Registry (WBDR).

He is Associate Editor for bleeding disorders of the Cochrane Collaboration, Thrombosis Research, and serves on the Editorial Boards of numerous journals including the Journal of Thrombosis and Haemostasis, and Haemophilia.

Outside Hemophilia, his current research interests include internet-based knowledge dissemination, systematic review and meta-analysis methodology, risk prediction and stratification, and artificial intelligence application to all of them.

He has authored over 300 peer reviewed papers totaling over 20,000 citations and a H-index of 59 (details available on his personal page Google Scholar). He has given many lectures, including educational lectures at many international conferences.

 

Key Publications

1.      Alfonso Iorio, Frederick A Spencer, Maicon Falavigna, Carolina Alba, Eddie Lang, Bernard Burnand, Tom McGinn, Jill Hayden, Katrina Williams, Beverly Shea, Robert Wolff, Ton Kujpers, Pablo Perel, Per Olav Vandvik, Paul Glasziou, Holger Schunemann, Gordon Guyatt. Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients. BMJ 2015;350:h870. doi: 10.1136/bmj.h870. No abstract available. PMID: 25775931.

2.      Athale A, Giguere A, Barbara A, Krassova S, Iorio A. Developing a two-sided intervention to facilitate shared decision-making in haemophilia: decision boxes for clinicians and patient decision aids for patients. Haemophilia. 2014 Nov;20(6):800-6. doi: 10.1111/hae.12495. Epub 2014 Oct 2. PubMed PMID: 25273544

3.      Marcucci M, Smith CT, Douketis JD, Tosetto A, Baglin T, Cushman M, Eichinger S, Palareti G, Poli D, Tait RC, Iorio A. Patient-level compared with study-level meta-analyses demonstrate consistency of D-dimer as predictor of venous thromboembolic recurrences. J Clin Epidemiol. 2013 Apr;66(4) : 415-25. Doi: 10.1016/j.jclinepi.2012.08.007. Epub 2013 Feb 8. PubMed PMID: 23395515.

4.      Iorio A, Puccetti P, Makris M. Clotting factor concentrate switching and inhibitor development in hemophilia A. Blood. 2012 Jul 26;120(4):720-7. Epub 2012 Jun 12. PubMed PMID: 22692511.

5.      Don-Wauchope AC, Sievenpiper JL, Hill SA, Iorio A. Applicability of the AGREE II Instrument in Evaluating the Development Process and Quality of Current National Academy of Clinical Biochemistry Guidelines. Clin Chem. 2012 Oct;58(10):1426-37. Epub 2012 Aug 9. PubMed PMID: 22879395.

Current Positions/Chairs:

  • Professor and Chair, Dept. of Health Research Methods, Evidence, and Impact
  • Director, Health Information Research Unit (HiRU)
  • Director, Hamilton Niagara Regional Hemophilia Program, McMaster University

Key Institutions

  • McMaster University
    Department of Health Research Methods, Evidence, and Impact

Publications

May 20, 2021

Terminal half-life of FVIII and FIX according to age, blood group and concentrate type: data from the WAPPS database

Authors
Versloot O, Iserman E, Chelle P, Germini F, Edginton AN, Schutgens REG, Iorio A, Fischer K; Pharmacokinetic (PK) Expert Working Group of the International Prophylaxis Study Group (IPSG).
Citation
J Thromb Haemost. 2021 May 20. doi: 10.1111/jth.15395. Epub ahead of print. PMID: 34013558.
December 5, 2020

Not All Patients Benefit from Switching to Ehl: Results from the Wapps Database

The 62nd ASH Annual Meeting and Exposition (Dec 5-8, 2020)
Authors
Versloot O, Iserman E, Chelle P, Germini,F, Mathew T, Iorio A, and Fischer K
Citation
December 5, 2020

Terminal Half-Life of Factor VIII/IX According to Age and Blood Group Based on 8550 Assessments.

The 62nd ASH Annual Meeting and Exposition (Dec 5-8, 2020)
Authors
Versloot O, Iserman E, Chelle P, Germini,F, Mathew T, Iorio A, and Fischer K.
Citation
November 5, 2020

Not All Patients Benefit from Switching to Ehl: Results from the Wapps Database

Authors
Versloot O, Iserman E, Chelle P, Germini,F, Mathew T, Iorio A, and Fischer K
Citation
Blood 2020; 136 (S1): 21-22.
November 5, 2020

Terminal Half-Life of Factor VIII/IX According to Age and Blood Group Based on 8550 Assessments

Authors
Versloot O, Iserman E, Chelle P, Germini,F, Mathew T, Iorio A, and Fischer K
Citation
Blood 2020; 136 (S1): 22-23